标题
Targeting AKT for cancer therapy
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 11, Pages 977-988
出版商
Informa UK Limited
发表日期
2019-10-09
DOI
10.1080/13543784.2019.1676726
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients.
- (2019) Cecile Vicier et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT isoform-specific expression and activation across cancer lineages
- (2018) Jue Wang et al. BMC CANCER
- Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial
- (2018) K. Kalinsky et al. Clinical & Translational Oncology
- Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
- (2018) Belinda van Zyl et al. ENDOCRINE-RELATED CANCER
- A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
- (2018) Carol Aghajanian et al. INVESTIGATIONAL NEW DRUGS
- AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.
- (2018) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Crosstalk in transition: the translocation of Akt
- (2018) Catheryn W. Gray et al. JOURNAL OF MATHEMATICAL BIOLOGY
- Capivasertib Active against AKT1-Mutated Cancers
- (2018) Cancer Discovery
- Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
- (2017) Eric Angevin et al. EUROPEAN JOURNAL OF CANCER
- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- 446PDPHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR IPATASERTIB (IPAT) WITH PACLITAXEL (P) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
- (2017) S.J. Isakoff et al. ANNALS OF ONCOLOGY
- AKT in cancer: new molecular insights and advances in drug development
- (2016) Prabhjot S. Mundi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models
- (2016) Oliver Politz et al. INTERNATIONAL JOURNAL OF CANCER
- Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53.
- (2016) Sungman Park et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor
- (2016) Jean-Marc Lapierre et al. JOURNAL OF MEDICINAL CHEMISTRY
- Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
- (2016) C. Stottrup et al. MOLECULAR CANCER THERAPEUTICS
- AKT signaling in ERBB2-amplified breast cancer
- (2016) F. Javier Carmona et al. PHARMACOLOGY & THERAPEUTICS
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- P5.01 * A first in human, dose escalation trial of MSC2363318A - a dual p70S6K/Akt inhibitor, for patients with advanced malignancies
- (2015) A. M. Tsimberidou et al. ANNALS OF ONCOLOGY
- 338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
- (2015) A. Tolcher et al. EUROPEAN JOURNAL OF CANCER
- Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies
- (2015) Weimin Fan et al. Future Medicinal Chemistry
- The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
- (2015) Seiji Mabuchi et al. GYNECOLOGIC ONCOLOGY
- A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer
- (2015) Analia Azaro et al. INVESTIGATIONAL NEW DRUGS
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
- (2015) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
- (2015) Kyung H. Yi et al. Oncotarget
- Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
- (2015) Marjorie J. Lindhurst et al. Scientific Reports
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- Abstract 4516: Evaluation of p70S6K/Akt inhibitor MSC2363318A in patient derived xenograft (PDX) models of breast cancer
- (2015) Bayard R. Huck et al. CANCER RESEARCH
- Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
- (2015) Yi Yu et al. PLoS One
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract C177: TAS-117, a highly selective non-ATP competitive inhibitor of AKT demonstrated antitumor activity in combination with chemotherapeutic agents and molecular targeted drugs.
- (2014) K. Ichikawa et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
- (2014) Melissa Dumble et al. PLoS One
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Regulation of YAP through an Akt-dependent process by 3, 3′-diindolylmethane in human colon cancer cells
- (2013) XIU JUAN LI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
- (2013) Matt Addie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
- (2013) Deepa Sampath et al. LEUKEMIA RESEARCH
- Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
- (2012) T. Sangai et al. CLINICAL CANCER RESEARCH
- Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
- (2012) D. A. Altomare et al. CURRENT MEDICINAL CHEMISTRY
- Suppression of survival signalling pathways by the phosphatase PHLPP
- (2012) Audrey K. O’Neill et al. FEBS Journal
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
- (2012) Siqing Fu et al. GYNECOLOGIC ONCOLOGY
- Identification of Akt Interaction Protein PHF20/TZP That Transcriptionally Regulates p53
- (2012) Sungman Park et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Mouse Models of Cancer
- (2011) Dong-Joo Cheon et al. Annual Review of Pathology-Mechanisms of Disease
- Akt, FoxO and regulation of apoptosis
- (2011) Xinbo Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Breast cancer statistics, 2011
- (2011) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract 2754: Phase I and pharmacokinetic (PK) study of two regimens combining the aurora kinase inhibitor AS703569 and gemcitabine in patients with advanced solid tumors
- (2011) Ahmad Awada et al. CANCER RESEARCH
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis
- (2011) Qing Xu et al. NUCLEIC ACIDS RESEARCH
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane
- (2010) N Berndt et al. CELL DEATH AND DIFFERENTIATION
- Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
- (2010) Christopher R. Garrett et al. INVESTIGATIONAL NEW DRUGS
- Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia
- (2010) Camilla Evangelisti et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis
- (2009) Alexandra Dieterle et al. INTERNATIONAL JOURNAL OF CANCER
- Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen
- (2009) John McLaughlin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Akt as a therapeutic target in cancer
- (2008) Linda S Steelman et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
- (2008) Qing-Bai She et al. PLoS One
- The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development
- (2008) Deborah K. Morrison TRENDS IN CELL BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started